This white paper explores the increasing challenges of drug development, where costs rise while productivity declines (Eroom's Law), and how artificial intelligence (AI) offers a solution to reverse this trend.
In this white paper, you will learn:
- How AI and machine learning are revolutionizing drug development.
- The importance of accurate Probability of Technical and Regulatory Success (PTRS) assessments in making informed decisions about drug candidates.
- How AI can overcome the limitations of traditional PTRS approaches, providing objective, data-driven insights.
- The benefits of AI-driven PTRS assessments, including increased efficiency, reduced costs, and better resource allocation in drug development.